



SEQUENCE LISTING

<110> Laus, Reiner  
Hakim, Itzhak  
Vidovic, Damir

- <120> Compositions and Methods for Enhancement  
of Major Histocompatibility Complex Class I Restricted  
Antigen Presentation

<130> 57636-8020.US00

<140> US 09/461,684  
<141> 1999-12-14

<150> US 60/112,324  
<151> 1998-12-14

<160> 10

<170> FastSEQ for Windows Version 4.0

<210> 1  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> pK

C,  
<400> 1  
Cys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
1 5 10 15  
Lys Lys Lys Lys Lys  
20

<210> 2  
<211> 25  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> pEA

<400> 2  
Cys Glu Ala Ala Ala Ala Ala Glu Ala Ala Ala Ala Glu Ala Ala  
1 5 10 15  
Ala Ala Ala Glu Ala Ala Ala Ala Ala  
20 25

<210> 3  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> HA

RECEIVED

MAY 29 2003

TECH CENTER 1600/2900

<400> 3  
 Cys Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Asn Gly Trp Glu  
   1                  5                  10                  15  
 Gly Met Ile Asp Gly Trp Tyr Gly  
                   20

<210> 4  
 <211> 45  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> tandem pEA/pK conjugate

<400> 4  
 Cys Glu Ala Ala Ala Ala Glu Ala Ala Ala Ala Glu Ala Ala  
   1                  5                  10                  15  
 Ala Ala Ala Glu Ala Ala Ala Ala Lys Lys Lys Lys Lys Lys  
                   20                  25                  30  
 Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
                   35                  40                  45

<210> 5  
 <211> 44  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> tandem HA/pK conjugate

<400> 5  
 Cys Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Asn Gly Trp Glu  
   1                  5                  10                  15  
 Gly Met Ile Asp Gly Trp Tyr Gly Lys Lys Lys Lys Lys Lys Lys  
                   20                  25                  30  
 Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys  
                   35                  40

<210> 6  
 <211> 21  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> added peptidic sequence with a combination of lys and arg residues, with  
 an N-terminal cys residue

<221> VARIANT  
 <222> (1)...(21)  
 <223> Xaa = Arg or Lys

<400> 6  
 Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
   1                  5                  10                  15  
 Xaa Xaa Xaa Xaa Xaa  
                   20

<210> 7  
 <211> 20  
 <212> PRT

<213> Artificial Sequence

<220>

<223> added peptidic sequence with a combination of lys and arg residues

<221> VARIANT

<222> (1)...(20)

<223> Xaa = Arg or Lys

<400> 7

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10 15

Xaa Xaa Xaa Xaa  
20

<210> 8

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> peptidic sequence with repeating subunits, with an N-terminal cys residue

<221> VARIANT

<222> (2)...(2)

<223> Xaa = Glu or Asp

<221> VARIANT

<222> (3)...(7)

<223> Xaa = Ala, Leu, Ile, Phe, Gly, Cys, Met or Val

<221> VARIANT

<222> (2)...(7)

<223> amino acids 2 to 7 comprise a subunit that is repeated three or more times

<400> 8

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5

<210> 9

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> peptidic sequence with repeating subunits

<221> VARIANT

<222> (1)...(1)

<223> Xaa = Glu or Asp

<221> VARIANT

<222> (2)...(6)

<223> Xaa = Ala, Leu, Ile, Phe, Gly, Cys, Met or Val

<221> VARIANT

<222> (1)...(6)

<223> amino acids 1 to 6 comprise a subunit that is repeated three or more times

<400> 9

Xaa Xaa Xaa Xaa Xaa Xaa  
1 5

<210> 10

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> OVA- derived peptide (OVA 257-264), recognized by the T cell hybridoma B3Z. (Jameson et al., 1993, J. Exp. Med. 177: 1541)

<400> 10

Ser Ile Ile Asn Phe Glu Lys Leu  
1 5